Robert Kim, M.D.

Robert Kim, M.D.

Chief Medical Officerat4D Molecular Therapeutics· In the 2023 proxy

Pay in FY20234D Molecular Therapeutics stock -8.8% the same year

Robert Kim, M.D. was paid $4.0M in FY2023 (Dec). 4D Molecular Therapeutics stock fell 8.8% that year.

Pay$100 in the stock at the end of FY22 → $91
Pay is from the Summary Compensation Table of each 4D Molecular Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. 4D Molecular TherapeuticsPublic company · 3 yr
    • Chief Medical Officer2023 – Present · 3 yrStock in role -36%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?